Information about Darifenacin
Liver safety of Darifenacin
Darifenacin has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Darifenacin
Darifenacin (dar" i fen' a sin) is anticholinergic agent with a degree of selectivity for the M3 subtype of muscarinic acetylcholine receptors which is found predominantly in the smooth muscle of the bladder. Darifenacin increases bladder capacity and decreases bladder contractions and the urgency of urination.
FDA approval information for Darifenacin
Darifenacin was approved for use in the United States in 2004 and indications include urinary urge incontinence and overactive bladder syndrome.
Dosage and administration for Darifenacin
Darifenacin is available in extended release tablets of 7.5 and 15 mg under the brand name Enablex. The recommended adult oral dose is 7.5 to 15 mg once daily.
Side effects of Darifenacin
Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, and urinary retention. Because of its selectivity for the M3 muscarinic receptor, darifenacin is believed to be less likely than other anticholinergic agents to cause central nervous system effects such as restlessness, confusion and hallucinations. anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.
- Overactive bladder syndrome agents - darifenacin, fesoterodine, flavoxate, hyoscyamine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium